The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.
In a new draft guidance, the FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing. The agency through a separate initiative also plans to make it easier for biosimilars to be developed as interchangeable with brand-name biologics, helping patients and pharmacists choose lower-cost options more easily.
Expensive biologic medications make up only 5% of prescriptions in the U.S. but account for 51% of total drug spending as of 2024. FDA-approved biosimilars are as safe and effective as the branded drugs, yet their market share remains below 20%. To date, FDA has approved 76 biosimilars, corresponding to a small fraction of approved biologics. By contrast, there are more than 30,000 approved generics, exceeding the number of approved brand drugs. Only about 10% of biologic drugs expected to lose patent protection in the next decade currently have a biosimilar in development.
Currently, in some circumstances, developers perform “switching studies” for biosimilars licensed as interchangeable – a step not required for generic drugs. These additional studies can slow development and create public confusion about biosimilar safety. The FDA now generally does not recommend switching studies. As industries and authorities adjust to this change, Echa and industry experts will continue to monitor advances in this area.
Reference:
FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs | FDA
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Diacetone Alcohol (DAA) is an aliphatic hydroxy ketone produced through the base-catalysed aldol addition of two acetone molecules. It contains both ketone and tertiary hydroxyl functionalities, offering excellent solvency and chemical reactivity.
As a high-boiling oxygenated solvent and valuable chemical intermediate, DAA finds broad application in paints and coatings, printing inks, adhesives, industrial cleaning, cosmetics, and textiles. It is also used as an intermediate in the production of mesityl oxide and MIBK. (4-methylpentan-2-one).
Kojic acid is a natural fungal metabolite produced through natural fermentation of carbohydrates. It works primarily as a tyrosinase inhibitor, suppressing melanin production to help reduce dark spots and even out skin tone. It also delivers antioxidant benefits, neutralizing free radicals and protecting skin cells from oxidative stress. With its naturally weak acidic profile, kojic acid is a multifunctional ingredient suited for brightening and protective skincare formulations.
(S)-Oxetan-2-yl-methanamine is a chiral oxetane-containing primary amine. The compound features a strained four-membered oxetane ring and an aminomethyl substituent, making it a valuable building block in modern medicinal chemistry. Due to its unique physicochemical properties, including increased polarity and metabolic stability compared with conventional alkyl groups, it is widely employed as an advanced pharmaceutical intermediate in drug discovery and development programs.